CUTISS closes CHF 56M Series C round and signs agreement with leading European burn center
10-09-2025 – CUTISS has announced the closing of its Series C round for a total of CHF 56M with existing and new investors, bringing total funds raised to more than CHF 125M.
CUTISS has closed its Series C round at CHF 56 million, bringing total funds raised to more than CHF 125 million. The proceeds will support the ongoing Phase 3 trials and commercialization of denovoSkin™, its personalized bioengineered skin graft, as well as advance the industrialization of CUTISS’ automation platform for tissue bioengineering and enable the launch of VitiCell®. “The successful closing and partnerships demonstrates confidence in our vision and ability to bring transformative skin therapies to patients,” said Dr. Daniela Marino, CEO and co-founder of CUTISS.
The company also signed an agreement with Rode Kruis Ziekenhuis (RKZ), a leading EU burn care center, which could become CUTISS’ first international production facility once denovoSkin™ is approved. With strong investor support and partnerships like RKZ and Tecan, CUTISS is preparing to scale its groundbreaking therapies and expand internationally.
Our heartfelt congratulations to the CUTISS team for the amazing milestone.
